Osivax
Get Full AccessDescription
- OSIVAX is a biotech start-up based in Lyon (France) and focused on vaccines. It has been created in 2017 as a spin-off of the French pharmaceutical company IMAXIO.OSIVAX develops a clinical-stage vaccine & immunotherapy pipeline based on oligoDOM®, its pro-immunogenic antigen re-engineering technology. OSIVAX aims to push its vaccine candidates up to phase II clinical trials, and then out-license them to biopharmaceutical companies for further development and commercialization.OSIVAX remains open to new collaborations, for partners who are seeking technologies to improve the immune response on otherwise poorly immunogenic antigens.
-
Headquarters:99, Rue De Gerland , Lyon, , United States
More -
Phone Number:
-
Website: https://www.osivax.com
-
Employees:27
-
Revenue:$10 - 50M
-
Legal Name:Osivax
-
Osivax's Social Media
-
Is this data correct?
-
| NAICS Code: 541713 |
Show More
Sell more in less time!
Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!
Frequently Asked Questions regarding Osivax
-
Where are Osivax's Headquarters?
Osivax's Headquarters are in 99, Rue De Gerland ,Lyon,,United States
-
What is Osivax's official website?
Osivax's official website is https://www.osivax.com
-
What is Osivax's Revenue?
Osivax's revenue is $10 - 50M
-
What is Osivax's NAICS code?
Osivax's NAICS code is 541713
-
How many employees are working in Osivax
Osivax has 27 employees
-
What is Osivax's Industry?
Osivax is in the industry of Biotechnology
-
Who is Osivax's CEO?
Osivax's CEO is Alexandre Levert
-
Who is Osivax's Chief Business Development Officer?
Osivax's Chief Business Development Officer is Delphine Guyon-Gellin